189 related articles for article (PubMed ID: 20967219)
1. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine.
Whitaker HC; Kote-Jarai Z; Ross-Adams H; Warren AY; Burge J; George A; Bancroft E; Jhavar S; Leongamornlert D; Tymrakiewicz M; Saunders E; Page E; Mitra A; Mitchell G; Lindeman GJ; Evans DG; Blanco I; Mercer C; Rubinstein WS; Clowes V; Douglas F; Hodgson S; Walker L; Donaldson A; Izatt L; Dorkins H; Male A; Tucker K; Stapleton A; Lam J; Kirk J; Lilja H; Easton D; ; ; ; Cooper C; Eeles R; Neal DE
PLoS One; 2010 Oct; 5(10):e13363. PubMed ID: 20967219
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels.
Xu X; Valtonen-André C; Sävblom C; Halldén C; Lilja H; Klein RJ
Cancer Epidemiol Biomarkers Prev; 2010 Aug; 19(8):2035-42. PubMed ID: 20696662
[TBL] [Abstract][Full Text] [Related]
3. MSMB gene rs10993994 polymorphism increases the risk of prostate cancer.
Peng T; Zhang L; Zhu L; Mi YY
Oncotarget; 2017 Apr; 8(17):28494-28501. PubMed ID: 28212531
[TBL] [Abstract][Full Text] [Related]
4. Validation of prostate cancer risk variants rs10993994 and rs7098889 by CRISPR/Cas9 mediated genome editing.
Wang X; Hayes JE; Xu X; Gao X; Mehta D; Lilja HG; Klein RJ
Gene; 2021 Feb; 768():145265. PubMed ID: 33122083
[TBL] [Abstract][Full Text] [Related]
5. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility.
Lou H; Yeager M; Li H; Bosquet JG; Hayes RB; Orr N; Yu K; Hutchinson A; Jacobs KB; Kraft P; Wacholder S; Chatterjee N; Feigelson HS; Thun MJ; Diver WR; Albanes D; Virtamo J; Weinstein S; Ma J; Gaziano JM; Stampfer M; Schumacher FR; Giovannucci E; Cancel-Tassin G; Cussenot O; Valeri A; Andriole GL; Crawford ED; Anderson SK; Tucker M; Hoover RN; Fraumeni JF; Thomas G; Hunter DJ; Dean M; Chanock SJ
Proc Natl Acad Sci U S A; 2009 May; 106(19):7933-8. PubMed ID: 19383797
[TBL] [Abstract][Full Text] [Related]
6. Association of prostate cancer susceptibility variant (MSMB) rs10993994 with risk of spermatogenic failure.
Wu W; Lu J; Yuan B; Qin Y; Chen M; Niu X; Xu B; Lu C; Xia Y; Chen D; Sha J; Wang X
Gene; 2013 Jul; 524(2):197-202. PubMed ID: 23608167
[TBL] [Abstract][Full Text] [Related]
7. A functional polymorphism in MSMB gene promoter is associated with prostate cancer risk and serum MSMB expression.
Xu B; Wang J; Tong N; Mi Y; Min Z; Tao J; Li P; Cheng G; Li J; Wang M; Tang J; Song N; Zhang Z; Zhang W; Wu H; Hua L; Feng N
Prostate; 2010 Jul; 70(10):1146-52. PubMed ID: 20333697
[TBL] [Abstract][Full Text] [Related]
8. Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.
Sjöblom L; Saramäki O; Annala M; Leinonen K; Nättinen J; Tolonen T; Wahlfors T; Nykter M; Bova GS; Schleutker J; Tammela TL; Lilja H; Visakorpi T
PLoS One; 2016; 11(3):e0150241. PubMed ID: 26939004
[TBL] [Abstract][Full Text] [Related]
9. A common prostate cancer risk variant 5' of microseminoprotein-beta (MSMB) is a strong predictor of circulating beta-microseminoprotein (MSP) levels in multiple populations.
Waters KM; Stram DO; Le Marchand L; Klein RJ; Valtonen-André C; Peltola MT; Kolonel LN; Henderson BE; Lilja H; Haiman CA
Cancer Epidemiol Biomarkers Prev; 2010 Oct; 19(10):2639-46. PubMed ID: 20736317
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive resequence analysis of a 97 kb region of chromosome 10q11.2 containing the MSMB gene associated with prostate cancer.
Yeager M; Deng Z; Boland J; Matthews C; Bacior J; Lonsberry V; Hutchinson A; Burdett LA; Qi L; Jacobs KB; Gonzalez-Bosquet J; Berndt SI; Hayes RB; Hoover RN; Thomas G; Hunter DJ; Dean M; Chanock SJ
Hum Genet; 2009 Dec; 126(6):743-50. PubMed ID: 19644707
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression.
FitzGerald LM; Zhang X; Kolb S; Kwon EM; Liew YC; Hurtado-Coll A; Knudsen BS; Ostrander EA; Stanford JL
Hum Mutat; 2013 Jan; 34(1):149-56. PubMed ID: 22887727
[TBL] [Abstract][Full Text] [Related]
12. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.
Whitaker HC; Warren AY; Eeles R; Kote-Jarai Z; Neal DE
Prostate; 2010 Feb; 70(3):333-40. PubMed ID: 19790236
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of influence of MSMB promoter rs10993994 polymorphisms on prostate cancer risk.
Fu S; Huang YL; Luan T; Li N; Wang HF; Wang JS
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9295-9303. PubMed ID: 31773691
[TBL] [Abstract][Full Text] [Related]
14. MSMB gene variant alters the association between prostate cancer and number of sexual partners.
Stott-Miller M; Wright JL; Stanford JL
Prostate; 2013 Dec; 73(16):1803-9. PubMed ID: 24037734
[TBL] [Abstract][Full Text] [Related]
15. Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness.
Bergström SH; Järemo H; Nilsson M; Adamo HH; Bergh A
Prostate; 2018 Mar; 78(4):257-265. PubMed ID: 29250809
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB.
Bicak M; Wang X; Gao X; Xu X; Väänänen RM; Taimen P; Lilja H; Pettersson K; Klein RJ
Hum Mol Genet; 2020 Jun; 29(10):1581-1591. PubMed ID: 32065238
[TBL] [Abstract][Full Text] [Related]
17. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk.
Chang BL; Cramer SD; Wiklund F; Isaacs SD; Stevens VL; Sun J; Smith S; Pruett K; Romero LM; Wiley KE; Kim ST; Zhu Y; Zhang Z; Hsu FC; Turner AR; Adolfsson J; Liu W; Kim JW; Duggan D; Carpten J; Zheng SL; Rodriguez C; Isaacs WB; Grönberg H; Xu J
Hum Mol Genet; 2009 Apr; 18(7):1368-75. PubMed ID: 19153072
[TBL] [Abstract][Full Text] [Related]
18. Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
Dahlman A; Edsjö A; Halldén C; Persson JL; Fine SW; Lilja H; Gerald W; Bjartell A
Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):369-75. PubMed ID: 20680031
[TBL] [Abstract][Full Text] [Related]
19. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
Kader AK; Sun J; Isaacs SD; Wiley KE; Yan G; Kim ST; Fedor H; DeMarzo AM; Epstein JI; Walsh PC; Partin AW; Trock B; Zheng SL; Xu J; Isaacs W
Prostate; 2009 Aug; 69(11):1195-205. PubMed ID: 19434657
[TBL] [Abstract][Full Text] [Related]
20. Mutation analysis of the MSMB gene in familial prostate cancer.
Kote-Jarai Z; Leongamornlert D; Tymrakiewicz M; Field H; Guy M; Al Olama AA; Morrison J; O'Brien L; Wilkinson R; Hall A; Sawyer E; Muir K; Hamdy F; Donovan J; Neal D; Easton D; Eeles R
Br J Cancer; 2010 Jan; 102(2):414-8. PubMed ID: 19997100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
